Randomized, phase III, double-blind, vehicle-controlled clinical trial to evaluate the safety and efficacy of 12 weeks of twice-daily azelaic acid foam, 15% in papulopustular rosacea - 09/05/15
Zoe D. Draelos, MD, Dermatology Consulting Services, High Point, NC, United States; Boni E. Elewski, MD, University of Alabama at Birmingham, Birmingham, AL, United States; Julie C. Harper, MD, Dermatology and Skin Care Center of Birmingham, P.C., Birmingham, AL, United States; Meike Sand MSc, Global Development, Bayer Healthcare, Berlin, Germany; Gerald Staedtler MSc, Global Development, Bayer Healthcare, Berlin, Germany; Richard Nkulikiyinka, MD, Global Development, Bayer Healthcare, Berlin, Germany; Kaweh Shakery, MD, Global Development, Bayer Healthcare, Berlin, Germany
Il testo completo di questo articolo è disponibile in PDF.| 100% sponsored by Bayer Dermatology. |
Vol 72 - N° 5S1
P. AB59 - maggio 2015 Ritorno al numeroBenvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?
